NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

NWBO is “in the catbird’s seat “ although it’s priced for death by the marketplace

Thanks PGSD for your super sleuthing re Dec 11th Boston NWBO CTO Dr. Marnix Bosch presenting
Quote:
"Outlining the key aspects of the DCVax technology that contribute to the positive clinical results"

THIS IS YET ANOTHER ADDITION to the

UPCOMING MOTHER of ALL TSUNAMIs in SOLID Tumors:

The STARS have been ALIGNING for the unveiling of Top Line Data on Ph3 DCVAX L BEFORE mid Dec 2019!

June 2019 ASCO with the eye witness identification of MRK's EVP Roger Perlmutter shaking hands with CEO Linda Powers by our oncologist iHub brethren:
AlphaPuppy! and Photonic5! along with prompting by Erik007 that began late August 2019:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151055015

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151005183

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151004805

The Sept 4, 2019 hiring from Merck of Dr. Duffy:
https://nwbio.com/nw-bio-expands-senior-management-team-with-dr-kevin-duffy-as-vice-president-medical-affairs-external-collaborations/

So the work in process jigsaw puzzle for evolving NWBO calendar CURRENTLY looks like this:

Oct 25 8:30 PST AM: UCLA's Dr. Linda Liau the Private Investigator for DCVAX L to present in Salt Lake City's Huntsman Cancer Center:

https://healthcare.utah.edu/huntsmancancerinstitute/events/2019/brain-tumor.php

SNO : FOUR DAYS 11/21/24 in Phoenix, AZ BIG EVENT (likely 2nd largest oncologists confab after May/June ASCO)

https://www.eventscribe.com/2019/sno/agenda.asp?pfp=FullSchedule

Lots of drop down menu's revealing most ALL of UCLA's Dr. Linda Liau's staff/associates: Dr.:Robert M. Prins & Dr. Timothy F. Cloughesy ETC ; John Hopkins Dr. Michael Lim (worked on DCVAX L).and Dr.Michael Lim is the Director of the Brain Cancer Immunology Laboratory at Johns Hopkins. See post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148242117

There are some slots left at SNO where NWBO can FILL? Would NOT rule it out YET!

Dec 6th UCLA's Dr. Linda Liau at Miami's 3rd Annual Brian Symposium :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151619108

http://MiamiBrainSymposium.BaptistHealth.net

Dec 11th NWBO's Chief Technical Officer Dr. Marnix Bosch:
This Glioblastoma Drug Development Summit Conference in Boston encompasses a who's who's
in GBM:

Prominent peers of Dr. Linda Liau on the East Coast: Boston's Dr. Patrick Wen:
https://www.dana-farber.org/find-a-doctor/patrick-y-wen

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma https://clincancerres.aacrjournals.org/content/early/2019/07/18/1078-0432.CCR-19-0261

Dr. Reardon was the Private Investigator on Celldex rGBM FAILED cancer vaccine rindopepimut: https://www.ascopost.com/issues/july-10-2016/expert-point-of-view-david-reardon-md/

https://glioblastoma-drugdevelopment.com/about/agenda/day-two/

==============================================================
maverick_1 Monday, 10/21/19 04:39:57 PM
Re: pgsd post# 248401
Post # of 248499
NWBO is “in the catbird’s seat “ although it’s priced for death by the marketplace

Thanks PGSD for your super sleuthing re Dec 11th Boston NWBO CTO Dr. Marnix Bosch presenting
Quote:
"Outlining the key aspects of the DCVax technology that contribute to the positive clinical results"

THIS IS YET ANOTHER ADDITION to the

UPCOMING MOTHER of ALL TSUNAMIs in SOLID Tumors:

The STARS have been ALIGNING for the unveiling of Top Line Data on Ph3 DCVAX L BEFORE mid Dec 2019!

June 2019 ASCO with the eye witness identification of MRK's EVP Roger Perlmutter shaking hands with CEO Linda Powers by our oncologist iHub brethren:
AlphaPuppy! and Photonic5! along with prompting by Erik007 that began late August 2019:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151055015

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151005183

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151004805

The Sept 4, 2019 hiring from Merck of Dr. Duffy:
https://nwbio.com/nw-bio-expands-senior-management-team-with-dr-kevin-duffy-as-vice-president-medical-affairs-external-collaborations/

So the work in process jigsaw puzzle for evolving NWBO calendar CURRENTLY looks like this:

Oct 25 8:30 PST AM: UCLA's Dr. Linda Liau the Private Investigator for DCVAX L to present in Salt Lake City's Huntsman Cancer Center:
https://healthcare.utah.edu/huntsmancancerinstitute/events/2019/brain-tumor.php

SNO : FOUR DAYS 11/21/24 in Phoenix, AZ BIG EVENT (likely 2nd largest oncologists confab after May/June ASCO)

https://www.eventscribe.com/2019/sno/agenda.asp?pfp=FullSchedule

Lots of drop down menu's revealing most ALL of UCLA's Dr. Linda Liau's staff/associates: Dr.:Robert M. Prins & Dr. Timothy F. Cloughesy ETC ; John Hopkins Dr. Michael Lim (worked on DCVAX L).and Dr.Michael Lim is the Director of the Brain Cancer Immunology Laboratory at Johns Hopkins. See post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148242117

There are some slots left at SNO where NWBO can FILL? Would NOT rule it out YET!

Dec 6th UCLA's Dr. Linda Liau at Miami's 3rd Annual Brian Symposium :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151619108

http://MiamiBrainSymposium.BaptistHealth.net

Dec 11th NWBO's Chief Technical Officer Dr. Marnix Bosch:
This Glioblastoma Drug Development Summit Conference in Boston encompasses a who's who's
in GBM:

Prominent peers of Dr. Linda Liau on the East Coast: Boston's Dr. Patrick Wen:
https://www.dana-farber.org/find-a-doctor/patrick-y-wen

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma https://clincancerres.aacrjournals.org/content/early/2019/07/18/1078-0432.CCR-19-0261

Dr. Reardon was the Private Investigator on Celldex rGBM FAILED cancer vaccine rindopepimut: https://www.ascopost.com/issues/july-10-2016/expert-point-of-view-david-reardon-md/

https://glioblastoma-drugdevelopment.com/about/agenda/day-two/

==============================================================
Re Yet ANOTHER reason for NO Bristol Myers interest in NWBO:

CELG sold to BMY! 2023 Ph3 GBM Results 700+ patients
https://clinicaltrials.gov/ct2/show/NCT03345095
======+=================================

AS FOR: Neil Woodford re FORBES:
803 views|Oct 20, 2019,9:24 am
The Fall Of Neil Woodford Will See New Fund Management Rules
Stephen PopeContributor
Markets
I focus on developments on economic and market aspects within Europe.
[+]
There is a saying that suggests when a rider falls from a horse, the first thing that they should do is climb back on. Neil Woodford, a well-known investment manager and active equestrian, may find that the horse that was his career has bolted and may prove hard to recapture, let alone remount.

Woodford Investment Management is closing its doors as Woodford was dismissed from its flagship fund. This has left many pensioners and small investors staring at significant losses with little idea of how they can recoup the lost funds.

The effect has created a large circle of ripples as the entire fund management industry is going to come under the scrutiny of regulators and politicians.

One can understand why the spotlight will be intense as Woodford, who at one time was the custodian of £30 billion ($38.1 billion) of assets under management was considered an industry superstar.

That might sound rather glib. So, let me put it some context. An investment of £10,000 ($12,700) in 1988 when Woodford began at Invesco Perpetual would have grown to almost £250,000 when he left in 2013. So high had his reputation risen that when he established his own firm, Woodford Equity Income Fund (WEIF), in 2014, he raised £1.7 billion ($2.16 billion) in a fortnight. One year later he was described by the BBC as “the man who can’t stop making money.”

Regulators will be concerned as thousands of individuals put large sums of money into his care. Indeed, for many, Woodford was their one and only fund. It therefore follows that they could have lost a significant proportion of their pension fund.

The recent timeline shows that in 2015 Woodford launched Woodford Patient Capital Trust (WPCT) to invest in early-stage U.K. firms. The WPCT fund attracted £800 million ($1.02 billion) when it floated in April 2015, proving to be the ever-biggest fundraising for an investment trust in the U.K.

WEIF performed extremely well, booking a gain of 20% in its first year and the assets rose to an incredible £6.7 billion ($8.5 billion) by the end of July.

In 2017 Woodford’s fortunes began to decline as a change in WPCT’s remit to allowed it to invest in more unlisted companies, as well as more firms outside the U.K. This was followed by a poor run of performance by several key investments leading the asset manager, Jupiter to withdraw £300 million ($381 million).

Over 2018 and 2019 WEIF almost broke its limits of holding only 10% of its assets in unquoted assets and, with further declines in asset value, the pace of investors pulling money accelerated to a such a rate that Woodford was unable to sell assets fast enough to keep up with withdrawal demand.

The administrator “gated” the fund in June in an attempt to prevent savers from withdrawing any further funds. Despite the inability of investors to withdraw money, Woodford continued to collect £65,000 a day in management fees leading to a significant increase in public and political criticism.

Investors in WEIF have lost 37% of their savings since 2016. They have been given an ominous warning by the administrators to expect further declines as the fund, which has sacked Woodford is wound up.

The investment behaviour which was overlooked when the funds were rising has drawn criticism as the returns moved into the red. The same is the case over the fact that since 2015 Woodford has collected £63 million ($80 million) in income payments.

Be in no doubt, this is a serious development as funds rarely get completely suspended unless a serious case of fraud has been uncovered. To echo the importance of this development Bank of England governor Mark Carney said the shuttering of Woodford’s funds highlighted the structural problem of open-ended investment funds, which offer the investors the right to take their money out whenever they like.

There will be a long and detailed enquiry that will delve into the operational process of charges and transparency of stock holdings. There will almost certainly be new regulations that will obligate fund managers to reveal the proportion of money held in illiquid assets.

On reflection, it would seem Woodford was too quick to accept so much inward investment and certainly placed too big a bet on illiquid assets. He ignored the critical test of liquidity—is there a realistic bid price when one needs it?

Get the best of Forbes to your inbox with the latest insights from experts across the globe.
Follow me on Twitter. Check out my website.

Stephen Pope
===================================================
Said this over 5 yrs ago and EVEN MORE APPLICABLE:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=104907802
================================================

Why I recommended to both Larry Smith and Flipper ALL to NO AVAIL over 5 yrs ago The Baker Bros versus FLAMEOUT Neil Woodford:

https://www.bloomberg.com/news/articles/2019-10-21/baker-brothers-biotech-bet-makes-730-million-in-overnight-bump
=====================================================

MUCH WORST than Neil Woodford is $30+ Bln with this other U.K. $Mgr: that I saw yesterday

========================================
https://www.cnn.com/2019/10/21/investing/china-wealth-americans/index.html
.=====================•==========================

Responses: Sniper Attacks on INCONSEQUENTIALS underscore your OWN INSECURITIES!